Once-Daily Treatments for Methicillin-Susceptible Staphylococcus aureus Bacteremia: Are They Good Enough?

Purpose of the Review Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia is a common cause of morbidity and mortality. First-line treatment requires frequent daily doses of an anti-staphylococcal beta-lactam. However, some physicians prescribe simpler once-daily regimens to improve compli...

Full description

Saved in:
Bibliographic Details
Published in:Current infectious disease reports 2017-11, Vol.19 (11), p.43-43, Article 43
Main Authors: Lother, Sylvain A., Press, Natasha
Format: Article
Language:English
Subjects:
Antibiotics
Bacterial infections
Clinical outcomes
Drug therapy
Gastroenteritis
Gastroenteritis (T Steiner
Hepatitis
Infectious Diseases
Intra-abdominal Infections
Medicine
Medicine & Public Health
Section Editor
Topical Collection on Intra-abdominal Infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of the Review Methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia is a common cause of morbidity and mortality. First-line treatment requires frequent daily doses of an anti-staphylococcal beta-lactam. However, some physicians prescribe simpler once-daily regimens to improve compliance and improve healthcare utilization. We reviewed the literature regarding advantages, pitfalls, and efficacy of once-daily treatment options for MSSA bacteremia. Recent Findings Several once-daily antibiotics are effective in vitro against MSSA (ceftriaxone, daptomycin, telavancin, dalbavancin, oritavancin, tedizolid, ertapenem, fluoroquinolones, and others), but there is insufficient evidence to support these agents for MSSA bacteremia. Ceftriaxone may be considered for therapy completion with MSSA bacteremia from osteomyelitis, and daptomycin may be considered in patients who cannot tolerate first-line therapy. However, they have not been compared to traditional second-line agents, and their role remains uncertain. Summary Current evidence does not support the use of once-daily treatment options for MSSA bacteremia.
ISSN:1523-3847
1534-3146
DOI:10.1007/s11908-017-0599-0